Cell therapy (NK cells) · Kills target cells, directed at CD1d · developed by ImmunityBio
AgenT-797 is an allogeneic off-the-shelf cell therapy comprising invariant natural killer T cells (iNKTs) expressing an invariant T-cell receptor and NKG2D. The cells recognize CD1d-restricted lipid ligands and stress ligands on tumor and infected cells, inducing pro-inflammatory cytokine secretion and direct tumor cell lysis. It is studied in community-acquired pneumonia, acute respiratory distress syndrome, and sepsis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07492875 | Phase 3 | Community-Acquired Pneumonia (CAP) | Withdrawn | IBRX |
| NCT07492888 | Phase 2 | Acute Respiratory Distress Syndrome | Withdrawn | IBRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome (ARDS)Community-Acquired Pneumonia (CAP)ImmunoparalysisLymphopeniaLymphopenia / Immunoparalysis in Critically Ill AdultsSepsisSevere Community-Acquired Pneum
Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.
See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IBRX catalysts and pipeline →